Molecular Pharmacology Program

The Omar Abdel-Wahab Lab

Share
Back to top

Research

Omar Abdel-Wahab
Omar Abdel-Wahab, MD
Chair, Molecular Pharmacology Program, SKI; Attending Physician, Leukemia Service

Omar Abdel-Wahab is the Chair of SKI Molecular Pharmacology Program and an Attending Physician on the Leukemia Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center.

View Lab Overview

The Omar Abdel-Wahab Lab Members

Featured News

In the Lab
Physician-scientist Omar Abdel-Wahab
Research Suggests How Boosting Neoantigens Can Make Immunotherapy More Effective
In mice, drugs that change the way proteins are assembled appear to make checkpoint inhibitor drugs work better.
In the Lab
Sloan Kettering Institute molecular biologist Christine Mayr
Scientists Find Cancer Drivers Hiding in a New Place
New findings from researchers at the Sloan Kettering Institute suggest that cancer causes may be lurking in the molecule that bridges DNA and protein.
In the Lab
MSK physician-scientist Omar Abdel-Wahab
Splicing May Be an Effective Target in the Fight against Cancer
New drugs are being developed that target part of the process to make proteins.

View All Featured News

Publications Highlights

Montoya S, Bourcier J, Noviski M, Lu H, Thompson MC, Chirino A, Jahn J, Sondhi AK, Gajewski S, Tan YSM, Yung S, Urban A, Wang E, Han C, Mi X, Kim WJ, Sievers Q, Auger P, Bousquet H, Brathaban N, Bravo B, Gessner M, Guiducci C, Iuliano JN, Kane T, Mukerji R, Reddy PJ, Powers J, Sanchez Garcia de Los Rios M, Ye J, Barrientos Risso C, Tsai D, Pardo G, Notti RQ, Pardo A, Affer M, Nawaratne V, Totiger TM, Pena-Velasquez C, Rhodes JM, Zelenetz AD, Alencar A, Roeker LE, Mehta S, Garippa R, Linley A, Soni RK, Skånland SS, Brown RJ, Mato AR, Hansen GM (co-corresponding), Abdel-Wahab O (co-corresponding), Taylor J (co-corresponding). Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127. Science. 2024 Feb 2;383(6682):eadi5798. doi: 10.1126/science.adi5798. Epub 2024 Feb 2. PMID: 38301010.

Knorr K, Rahman J, Erickson C, Wang E, Monetti M, Li Z, Ortiz-Pacheco J, Jones A, Lu SX, Stanley RF, Baez M, Fox N, Castro C, Marino AE, Jiang C, Penson A, Hogg SJ, Mi X, Nakajima H, Kunimoto H, Nishimura K, Inoue D, Greenbaum B, Knorr D, Ravetch J (co-corresponding), Abdel-Wahab O (co-corresponding). Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemia. Nat Cancer. 2023 Oct 23. doi: 10.1038/s43018-023-00656-2. Epub ahead of print. PMID: 37872381.

Mi X, Penson A, Abdel-Wahab O, Mailankody S. Genetic Basis of Relapse after GPRC5D-Targeted CAR T Cells. N Engl J Med. 2023 Oct 12;389(15):1435-1437. doi: 10.1056/NEJMc2308544. PMID: 37819961.

Wang E, Pineda JMB, Kim WJ, Chen S, Bourcier J, Stahl M, Hogg SJ, Bewersdorf JP, Han C, Singer ME, Cui D, Erickson CE, Tittley SM, Penson AV, Knorr K, Stanley RF, Rahman J, Krishnamoorthy G, Fagin JA, Creger E, McMillan E, Mak CC, Jarvis M, Bossard C, Beaupre DM, Bradley RK, Wang E, Pineda JMB, Kim WJ, Chen S, Bourcier J, Stahl M, Hogg SJ, Bewersdorf JP, Han C, Singer ME, Cui D, Erickson CE, Tittley SM, Penson AV, Knorr K, Stanley RF, Rahman J, Krishnamoorthy G, Fagin JA, Creger E, McMillan E, Mak CC, Jarvis M, Bossard C, Beaupre DM, Bradley RK (co-corresponding), Abdel-Wahab O (co-corresponding). Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia. Cancer Cell. 2023 Jan 9;41(1):164-180.e8. doi: 10.1016/j.ccell.2022.12.002. Epub 2022 Dec 22. PMID: 36563682; PMCID: PMC9839614.

Chen S, Vedula RS, Cuevas-Navarro A, Lu B, Hogg SJ, Wang E, Benbarche S, Knorr K, Kim WJ, Stanley RF, Cho H, Erickson C, Singer M, Cui D, Tittley S, Durham BH, Pavletich TS, Fiala E, Walsh MF, Inoue D, Monette S, Taylor J, Rosen N, McCormick F, Lindsley RC, Castel P, Abdel-Wahab O. Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation. Cancer Discov. 2022 Oct 5;12(10):2434-2453. doi: 10.1158/2159-8290.CD-21-1631. PMID: 35904492;

View All Publications

People

Omar Abdel-Wahab

Omar Abdel-Wahab, MD

Chair, Molecular Pharmacology Program, SKI; Attending Physician, Leukemia Service

  • Physician-scientist Omar Abdel-Wahab studies the functional genomics of hematopoietic malignancies.
  • MD, Duke University School of Medicine
[email protected]
Email Address
View physician profile
Physician profile

Members

Yuxi Ai

Research Scholar

Salima Benbarche
Salima Benbarche

Senior Research Scientist

Cynthia Castro
Cynthia Castro

Research Technician

Bing-Yi Chen

Research Scholar

Nina Fox
Nina Fox

Research Technician

Takeshi Fujino

Research Fellow

Won Kim

Graduate Student

Alex Lewis

Research Technician

Jennifer Lewis

Medical Student

Bin Lu, Research Associate
Bin Lu

Research Associate

Xiaoli Mi

Fellow

Jahan Rahman
Jahan Rahman

Computational Biologist II

Erich Sabio

Senior Research Scientist

Robert Stanley
Robert Stanley

Fellow

Steven Tittley
Steven Tittley

Research Lab Manager

Kenyon Weis

Research Technician

Pu Zhang

Research Scholar

Qian Zhang

Research Scholar

Lab Alumni
Jihae Ahn
Jihae Ahn

Volunteer

Shlomzion Aumann
Shlomzion Aumann

Research Fellow

Lillian Bitner, Research Technician
Lillian Bitner

Research Technician

Jessie Bourcier
Jessie Bourcier

Research Fellow

Anna Chan

Research Technician

Sisi Chen
Sisi Chen

Research Scholar

Ha Na Cho, Research Assistant
Hana Cho

Research Assistant

Young Rock Chung
Young Rock Chung

Research Technician

Daniel Cui
Daniel Cui

Research Technician

Benjamin Durham (Pathology)
Benjamin Durham

Assistant Attending Pathologist

Caroline Erickson
Caroline Erickson

Research Technician

Luisa Escobar Hoyos

Research Fellow

Simon Hogg
Simon Hogg

Research Fellow

Monisha Hosier
Monisha Hosier

Administrative Assistant II

Daichi Inoue, Visiting Investigator
Daichi Inoue

Visiting Investigator

Michelle Ki
Michelle Ki

Research Technician

Eunhee Kim
Eunhee Kim

Research Fellow

Min Kim
Min Kim

Research Technician

Katherine Knorr
Katherine Knorr

Fellow

Pictured: Stanley Lee
Stanley Lee

Research Associate

Bo Liu, Research Associate
Bo Liu

Research Associate

Sydney Lu, Research Fellow
Sydney Lu

Assistant Member, Myeloma Service

Jean Baptiste Micol
Jean Baptiste Micol

Research Fellow

Alessandro Pastore, Senior Research Scientist
Alessandro Pastore

Senior Research Scientist

Alexander Penson, PhD
Alexander Penson

Senior Computational Biologist

Danielle Richards
Danielle Richards

Program Assistant

Ruth Saganty
Ruth Saganty
Michael Singer
Michael Singer

Research Technician

Justin Taylor

Instructor (Dept. of Medicine)

Eric Wang
Eric Wang

Research Scholar

Akihide Yoshimi, Senior Research Scientist
Akihide Yoshimi

Senior Research Scientist

Xiao Zhang
Lab Affiliations

Achievements

  • Josie Robertson Investigator (2012-2017)
  • Seldin-Smith Award for Pioneering Research, American Society of Clinical Investigation
  • Pershing Square Sohn Prize for Young Investigators in Cancer Research
  • Leukemia & Lymphoma Society Clinical Scholar Award
  • William Dameshek Prize, American Society of Hematology
Read more
  • Joanne Levy Memorial Award for Outstanding Achievement, American Society of Hematology
  • V Scholar Award, V Foundation
  • Junior Faculty Scholar Award, American Society of Hematology (ASH)
  • Damon Runyon Clinical Investigator Award

Lab News & Events

Upcoming event

Decoding and Recoding Stem-niche Crosstalk in Regeneration, Cancer and Fibrosis

Memorial Sloan Kettering Cancer Center
Zuckerman Research Center
417 East 68th Street
Room ZRC-105
New York, NY 10065

View all upcoming events

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Omar Abdel-Wahab discloses the following relationships and financial interests:

  • AIchemy, Inc.
    Equity; Professional Services and Activities (Uncompensated)
  • Array Biopharma
    Professional Services and Activities
  • AstraZeneca
    Professional Services and Activities
  • Codify Therapeutics, Inc.
    Equity; Intellectual Property Rights; Professional Services and Activities (Uncompensated)
  • Envisagenics
    Equity; Professional Services and Activities (Uncompensated)
  • Epizyme
    Intellectual Property Rights
  • Harmonic Discovery Inc.
    Equity
  • Janssen Global Services, LLC
    Professional Services and Activities
  • Loxo Oncology
    Professional Services and Activities
  • Pfizer, Inc.
    Professional Services and Activities

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures

Related topics: